Skip to main content
Fig. 6 | Journal of Neuroinflammation

Fig. 6

From: Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis

Fig. 6

RatMOG EAE brain and spinal cord single cell gene expression and effects of remibrutinib on microglia. a Cell populations detected by scRNA-seq. The scRNA-seq profiling of brains and spinal cords of RatMOG EAE mice showed 13 different cell types, including stromal cells (fibroblasts, endothelial cells), all major immune cell types recruited in the CNS (B cells, T cells, DCs, monocytes and macrophages), and resident cells of the CNS: neurons, neuroepithelial cells, astrocytes, oligodendrocytes and microglia, which we further classified in HM and DAM. b The UMAP representation of the identified cell types in brains and spinal cords of EAE mice showed that BTK was mostly expressed in microglia, myeloid cells and B cells. c The analysis of the neuroinflammatory gene signature in homeostatic and disease-associated microglia showed significant effects of remibrutinib in brain and spinal cord at both timepoints (p < 0.001, one-tailed Mann–Whitney U test)

Back to article page